Adagene (NASDAQ:ADAG – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Adagene to post earnings of ($0.33) per share for the quarter.
Adagene Stock Performance
Shares of NASDAQ:ADAG opened at $1.77 on Tuesday. The firm has a 50 day moving average of $1.88 and a 200-day moving average of $2.19. Adagene has a 12 month low of $1.64 and a 12 month high of $3.58.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on ADAG shares. HC Wainwright raised their target price on Adagene from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday, January 27th. Morgan Stanley lowered Adagene from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 31st.
About Adagene
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
Featured Stories
- Five stocks we like better than Adagene
- Investing in the High PE Growth Stocks
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- The How and Why of Investing in Gold Stocks
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.